Skip to content
OpenCapital
Get started

Kyverna Therapeutics, Inc. KYTX Q2 2025 earnings

Reported August 12, 2025 · Before market open

Diluted EPS-$0.97Beat by $0.03
EPS estimate-$1.00

Next report

Aug 11, 2026 (In 4 weeks)
EPS estimate-$0.67

Financials

Q2 2025

Income statement

See full
Operating income-$44.4M-32.8%
Net income-$42.1M-46.1%
EPS (diluted)-$0.97-44.8%

Balance sheet

See full
Cash & equivalents$53.4M-59.4%
Total debt$5.9M-46.2%
Total equity$184.4M-44.7%
Total assets$226.5M-37.6%

Cash flow

See full
Operating cash flow-$31.9M-32.2%
CapEx$4.0K-99.6%
Free cash flow-$32.0M-26.8%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$137.87M-57.4%
Enterprise value$90.35M-55.5%

Returns & leverage

See full
Return on equity-61.3%—
Debt / equity0×0.0×
Current ratio5.4×-9.5×

Versus estimates

Diluted EPS

Q1 2026-$0.66Beat by $0.09Q4 2025-$0.80Beat by $0.04Q3 2025-$0.85Beat by $0.12
Q2 2025-$0.97Beat by $0.03
Q1 2025-$1.03Beat by $0.18Q4 2024-$0.88Miss by $0.01

Ask the moment Kyverna Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Kyverna Therapeutics, Inc. report Q2 2025 earnings?
Kyverna Therapeutics, Inc. (KYTX) reported Q2 2025 earnings on August 12, 2025 before market open.
What were Kyverna Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Kyverna Therapeutics, Inc. reported diluted EPS of $-0.97 for Q2 2025.
Did Kyverna Therapeutics, Inc. beat estimates in Q2 2025?
EPS beat the consensus estimate of $-1.00 by $0.03.
How did Kyverna Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 44.8% from $-0.67.
Where can I find Kyverna Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-107321) directly on SEC EDGAR. The filing index links above go to sec.gov.